XILIO THERAPEUTICS INC's ticker is and the CUSIP is 98422T100. A total of 30 filers reported holding XILIO THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $99,981 | -22.5% | 47,384 | -3.7% | 0.00% | – |
| Q2 2023 | $128,933 | -20.3% | 49,211 | -3.5% | 0.00% | – |
| Q1 2023 | $161,686 | +21.6% | 51,005 | +3.2% | 0.00% | – |
| Q4 2022 | $132,991 | -1.5% | 49,439 | +6.6% | 0.00% | – |
| Q3 2022 | $135,000 | -2.9% | 46,358 | -2.7% | 0.00% | – |
| Q2 2022 | $139,000 | -93.4% | 47,663 | -84.1% | 0.00% | – |
| Q1 2022 | $2,119,000 | -59.1% | 299,756 | -7.5% | 0.00% | – |
| Q4 2021 | $5,184,000 | – | 324,094 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RiverVest Venture Management LLC | 1,441,444 | $10,191,000 | 10.46% |
| AJU IB Investment Co., Ltd. | 667,742 | $4,721,000 | 7.29% |
| Atlas Venture Life Science Advisors, LLC | 2,759,344 | $19,509,000 | 2.47% |
| Bain Capital Life Sciences Investors, LLC | 2,805,413 | $19,834,000 | 1.93% |
| Soleus Capital Management, L.P. | 477,495 | $3,376,000 | 0.44% |
| Monashee Investment Management LLC | 163,066 | $1,153,000 | 0.33% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,078,692 | $14,696,000 | 0.33% |
| RA Capital Management | 2,002,217 | $14,156,000 | 0.31% |
| HARVARD MANAGEMENT CO INC | 416,059 | $2,942,000 | 0.30% |
| Rock Springs Capital Management LP | 1,191,094 | $8,421,000 | 0.21% |